Share this article
TUCSON, Ariz., May 19, 2021 /PRNewswire/
Critical Path Institute (C-Path) today announced the appointment of Robert M. Califf, MD, MACC, head of Clinical Policy and Strategy for Google parent company Alphabet s Verily Life Sciences and Google Health divisions, to C-Path s Board of Directors. Califf served as the U.S. Food and Drug Administration (FDA) Commissioner under President Barack Obama s administration from 2016-2017.
Robert M. Califf, MD, MACC
A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.
email article
Extended therapeutic-level prophylactic anticoagulation with rivaroxaban (Xarelto) for COVID-19 patients with elevated D-dimer levels wasn t better and carried more bleeding risk than lower hospital-only doses, the ACTION trial showed.
Standard prophylactic-level dosing actually won on mortality, duration of hospitalization, and duration of oxygen use through 30 days more often compared with the more intensive regimen, reported Renato Lopes, MD, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, at the virtual American College of Cardiology (ACC) meeting.
The trial randomized 615 patients to a standard approach of in-hospital prophylactic-dose anticoagulation or to a strategy with rivaroxaban (20 mg daily in hospital) if stable or enoxaparin (1 mg/kg twice daily) if unstable while in the hospital then rivaroxaban continued through day 30 whether still in the hospital or discharged home.
May 19, 2021
Adding antibiotics to usual care does not improve outcomes for people with the lung disease idiopathic pulmonary fibrosis (IPF), according to the findings from a multi-center, phase 3 clinical trial sponsored by Weill Cornell Medicine.
Importantly, the investigators note that although the trial had negative findings, the novel way it was designed and conducted could pave the way for future studies that are less expensive and easier to conduct. The research was published May 11 in JAMA: The Journal of the American Medical Association.
“IPF is a rare but fatal disorder that has a prognosis worse than most cancers and, unfortunately, has very limited therapeutic options,” said lead author Dr. Fernando J. Martinez, the Bruce Webster Professor of Internal Medicine at Weill Cornell Medicine and chief of pulmonary and critical care medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “There has been a lot of interest in trying to de
C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Credit: PCORI
WASHINGTON, DC People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, whether they took a high or low dose of aspirin, according to a study presented today at ACC.21, the American College of Cardiology s 70th Annual Scientific Session and published in the
New England Journal of Medicine.
CVD and atherosclerosis, in particular, which is a narrowing and hardening of the arteries is a leading cause of death for men, women, and most racial and ethnic groups in the United States, with estimated direct costs of $214 billion, according to the American Heart Association. Millions of Americans with CVD take recommended aspirin therapy to help reduce their risk of heart attack and stroke, a decades-long practice that has, until now, lacked definitive research studying the doses that work best for patients a